Kevin Robert Fales

This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2008-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Robert Fales. Retrieved from https://idiyas.com/inventor/kevin-robert-fales

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 1)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 8.2

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

4 out of 4,514

Eli Lilly and Company

patents

Years Active: 2008-2021

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10934280 - Condensed thiophene derivatives useful as NaPi-IIb inhibitors (2021-03-02),

2. 9776992 - 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers (2017-10-03),

3. 7935722 - Tetrahydrocarbazole derivatives useful as androgen receptor modulators (2011-05-03),

4. 7411072 - Tricyclic steroid hormone nuclear receptor modulators (2008-08-12),

Title: Kevin Robert Fales: Innovator in Pharmaceutical Chemistry

Introduction

Kevin Robert Fales is a notable inventor based in Avon, Indiana, who has made significant contributions to the field of pharmaceutical chemistry. With a total of four patents to his name, Fales has focused on developing innovative compounds that address critical health issues.

Latest Patents

Among his latest patents, Fales has developed condensed thiophene derivatives that serve as NaPi-IIb inhibitors. This invention provides compounds that can be utilized in treating hyperphosphatemia, chronic kidney disease, and cardiovascular diseases associated with chronic kidney disease. Another significant patent involves 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds. These formulations are designed to act as AICARFT inhibitors in cancer treatment, showcasing Fales' commitment to advancing medical science.

Career Highlights

Fales is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to focus on innovative drug development, contributing to the company's mission of improving patient outcomes through advanced therapies.

Collaborations

Throughout his career, Fales has collaborated with esteemed colleagues, including Jonathan Edward Green and Prabhakar Kondaji Jadhav. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Kevin Robert Fales exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations highlight his dedication to improving healthcare solutions.

Profile summary based on public USPTO records.